Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Early Hematologic and Liver Biochemical Dynamics During Pegylated Interferon-α-2b Therapy and Their Associations With Subsequent HBsAg Clearance in Chronic HBV Infection: A Dual-Center Landmark Cohort Study.

Created on 20 Nov 2026

Authors

Runci Jiang, Shuqin Cheng, Meiqi Zhao, Fengmei Wang

Published in

Virus research. Pages 199843. Nov 19, 2026. Epub Nov 19, 2026.

Abstract

The relevance of routine laboratory changes during pegylated interferon therapy remains uncertain. We examined associations between early laboratory changes and subsequent hepatitis B surface antigen (HBsAg) clearance in chronic hepatitis B virus infection.
This retrospective two-center cohort included adults receiving pegylated interferon-α-2b (PEG-IFNα-2b). Eight hematologic and liver biochemical markers were measured at baseline and weeks 12 and 24. A week-24 landmark separated early laboratory changes from subsequent HBsAg clearance through week 72. Linear mixed-effects models evaluated longitudinal patterns, and discrete-time survival models assessed associations after adjustment for clinical covariates and week-24 HBsAg. Benjamini-Hochberg correction addressed multiple testing, and incremental prediction was evaluated using bootstrap internal validation.
Among 269 patients, 47 (17.5%) achieved HBsAg clearance after week 24 and by week 72. Greater lymphocyte recovery during weeks 12-24 was associated with subsequent clearance (adjusted HR per 1-SD increase, 1.93; 95% CI, 1.43-2.62; FDR-adjusted P < 0.001). This association persisted after further adjustment for HBsAg kinetics and in ridge-penalized analyses. In the complete-case analysis (n = 267), adding lymphocyte change to the model increased the optimism-corrected week-72 AUC from 0.757 to 0.805; the corrected calibration slope was 0.548. Latent trajectory classes were not significantly associated with HBsAg clearance.
Greater lymphocyte recovery during weeks 12-24 remained associated with subsequent HBsAg clearance after adjustment for HBsAg kinetics. This routinely available measure warrants prospective validation as an on-treatment response marker.

PMID:
43057657
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement